S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:SNCE

Science 37 - SNCE Stock Forecast, Price & News

$0.44
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.42
$0.47
50-Day Range
$0.37
$0.75
52-Week Range
$0.32
$9.97
Volume
542,330 shs
Average Volume
406,050 shs
Market Capitalization
$51.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Science 37 MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
756.4% Upside
$3.75 Price Target
Short Interest
Healthy
1.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Science 37 in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$4,050 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.90) to ($0.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

86th out of 1,054 stocks

Commercial Physical Research Industry

2nd out of 17 stocks


SNCE stock logo

About Science 37 (NASDAQ:SNCE) Stock

Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

SNCE Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Science 37 Reports Third Quarter 2022 Financial Results
See More Headlines
Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

SNCE Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNCE
Fax
N/A
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+756.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-94,330,000.00
Pretax Margin
-66.45%

Debt

Sales & Book Value

Annual Sales
$59.60 million
Book Value
$1.06 per share

Miscellaneous

Free Float
111,531,000
Market Cap
$51.09 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Mr. David Coman (Age 52)
    CEO & Director
    Comp: $787.05k
  • Ms. Christine A. Pellizzari J.D. (Age 54)
    Chief Legal & HR Officer and Sec.
    Comp: $606.91k
  • Mr. Mike Zaranek (Age 51)
    Chief Financial Officer
  • Troy Bryenton
    Chief Technology Officer
  • Ms. Margie Gimbel Kooman
    VP of Marketing & Communications
  • Mr. Drew Bustos
    Chief Strategy & Marketing Officer
  • Mr. Jonathan Cotliar M.D. (Age 50)
    Chief Medical Officer
  • Ms. Darcy Forman (Age 47)
    Chief Delivery Officer
  • Ms. Elisa Cascade
    Chief Product Officer
  • Mr. Michael Shipton (Age 50)
    Chief Commercial Officer













SNCE Stock - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNCE shares.
View SNCE analyst ratings
or view top-rated stocks.

What is Science 37's stock price forecast for 2023?

5 analysts have issued 12-month price objectives for Science 37's stock. Their SNCE share price forecasts range from $2.00 to $7.00. On average, they predict the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 756.4% from the stock's current price.
View analysts price targets for SNCE
or view top-rated stocks among Wall Street analysts.

How have SNCE shares performed in 2023?

Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE shares have increased by 5.5% and is now trading at $0.4379.
View the best growth stocks for 2023 here
.

Are investors shorting Science 37?

Science 37 saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,060,000 shares, a drop of 24.3% from the December 31st total of 1,400,000 shares. Based on an average daily trading volume, of 361,400 shares, the short-interest ratio is currently 2.9 days. Currently, 1.4% of the company's shares are short sold.
View Science 37's Short Interest
.

When is Science 37's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our SNCE earnings forecast
.

How were Science 37's earnings last quarter?

Science 37 Holdings, Inc. (NASDAQ:SNCE) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.04. The firm earned $16.25 million during the quarter, compared to analysts' expectations of $20.60 million. Science 37 had a negative net margin of 66.46% and a negative trailing twelve-month return on equity of 72.32%.

What guidance has Science 37 issued on next quarter's earnings?

Science 37 issued an update on its FY 2022 earnings guidance on Saturday, December, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $68.20 million-$69.20 million, compared to the consensus revenue estimate of $80.68 million.

What is Science 37's stock symbol?

Science 37 trades on the NASDAQ under the ticker symbol "SNCE."

How do I buy shares of Science 37?

Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Science 37's stock price today?

One share of SNCE stock can currently be purchased for approximately $0.44.

How much money does Science 37 make?

Science 37 (NASDAQ:SNCE) has a market capitalization of $51.09 million and generates $59.60 million in revenue each year. The company earns $-94,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Science 37 have?

The company employs 601 workers across the globe.

How can I contact Science 37?

Science 37's mailing address is 250 W 55TH ST. #3401, NEW YORK NY, 10019. The official website for the company is www.lifesciacquisition.com. The company can be reached via phone at 984-377-3737 or via email at investment@lifesciacquisition.com.

This page (NASDAQ:SNCE) was last updated on 1/28/2023 by MarketBeat.com Staff